Safety Pharmacology
WuXi AppTec’s Safety Pharmacology group profiles compounds for potential adverse drug reactions at various R&D stages, thereby helping to deliver high-quality drug candidates faster and at lower cost.
Electrophysiology
- Provides integrated risk assessment on cardiosafety for compounds at various discovery and development stages on hERG and other cardiac ion channels.
- The state-of-the-art automated QPatch- HT system (48 channels) enables higher throughput, lower cost, and better consistency for hERG channel recordings.
- Conventional patch clamp assay and tissue level recording (e.g., on Purkinje fiber or isolated heart) provides detailed mechanistic information for compounds identified with QPatch.
- Automated Patch Clamp
- QPatch assay for hERG as a safety target
- QPatch assay for other cardiosafety channels
- Conventional Patch Clamp
- MOA studies for lead compounds
- Tissue level recording
- GLP hERG assay provides quality data for registration purposes
The state-of-the-art automated QPatch-HT system (48 channels) enables higher throughput, lower cost, and better consistency for hERG channel recordings.
In Vitro Pharmacology
- Addresses off-target based adverse drug reactions (ADR) and promiscuity of compounds. Such information may help guide compounds of interest through downstream in vivo tests for potential liabilities.
- Biochemical Assay
- Receptor ligand binding assays
- Kinase and protease assays
- Cell-based Assay
- FLIPR (Ca or Membrane Potential) based assays for ion channels or transporters
- FLIPR or GTPy_S assay for functional GPCRs
Early Toxicology
- Provides an early warning on potential genotoxicity for compounds during lead optimization. These assays are predictive of the GLP development full-panel Ames test as well as in vivo Micronucleus test, but with lower compound consumption and faster turnaround.
- Genotoxicity Assay
- Mini-Ames
- High-content Micronucleus